Dantrolene for Treatment of Hyperthermia in Subarachnoidal Hemorrhage (SAH)

• Status: Terminated
• Trial end date: 2011-03-01
• Target enrollment: 0
• Participant gender: All

Summary

Dantrolene is used to prevent hyperthermia in intensive care patients suffering from subarachnoidal hemorrhage.

• Phase: Phase 2/Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Medical University of Vienna
• Treatments: Dantrolene

Criteria

Inclusion Criteria:

• neurosurgical patients after subarachnoidal hemorrhage

• breathing spontaneously or being ventilator dependant

• sustained fever (≥38ºC for more than an hour) without an identifiable infectious cause.

Exclusion Criteria:

• infection

• pregnancy

• arrhythmia

• muscular dystrophia

• acute liver disease